
News from pharmtech.com
We’ve assigned a media bias rating of Center to pharmtech.com. You can read more about our methodology here.
If you want to know if pharmtech.com is credible or reliable, look no further. We rank pharmtech.com as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top pharmtech.com News

FDA · United StatesFast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac diseaseCandidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populationsSee the Story
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
67% Left coverage: 9 sources
Market Demands and Emerging Technologies Shape Outsourcing Models
100% Center coverage: 1 sources
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
100% Center coverage: 1 sources
Guidance on Quality Culture Standards
100% Center coverage: 1 sources